of this Form 8-K shall be deemed to be furnished and not filed: 99.1 | Press Release issued by Entrada Therapeutics, Inc. on November 5, 2026 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entrada Therapeutics, Inc. Date: November 5, 2026 | /s/ Dipal Doshi Dipal Dosh…

Other Events. Update on ENTR-601-45 On October 14, 2026, the Company announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45 in ambulatory participants with a confirmed mutation in the DMD gene amenable to exon 45 skipping. ELEVATE-45-201 is a global, two-part, randomized, double-blind, placebo-controlled Phase 1/2 study evaluating the safety, tolerability and eff…

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference…

Annual board election held in a virtual-only format.

of this Form 8-K shall be deemed to be furnished and not filed: 99.1 Press Release issued by Entrada Therapeutics, Inc. on May 7 , 2026 99.2 Press Release issued by Entrada Therapeutics, Inc. on May 7, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entrada Therape…

Results of Operations and Financial Condition. On February 26, 2026, Entrada Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes…

Other Events. On January 8, 2026, the Company reported its progress across its portfolio of RNA-based therapeutics for the treatment of neuromuscular and ocular diseases. The Company completed dosing of Cohort 1 of the global Phase 1/2 multiple ascending dose (MAD) portion of the clinical study of ENTR-601-44 in ambulatory patients living with DMD who are amenable to exon 44 skipping, and transitioned to the open label, Phase 2 portion of the study. The Company is on track to report ELEVATE-4…

of this Current Report on Form 8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Results of Operations and Financial Condition. On November 6, 2025, Entrada Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes…

Results of Operations and Financial Condition. On August 6, 2025, Entrada Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Sect…

Director — Maha Radhakrishnan, M.D.: Dr. Maha Radhakrishnan was appointed as a new director and joined the Audit Committee.

Results of Operations and Financial Condition. On May 8, 2025, Entrada Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Sectio…

Costs Associated with Exit or Disposal Activities. On April 29, 2025, the board of directors of Entrada Therapeutics, Inc. (the “Company”) approved a strategic plan designed to increase the focus of the Company’s resources on its expanding portfolio of clinical candidates in Duchenne muscular dystrophy (“DMD”) and key preclinical programs. Effective May 2, 2025, the new strategic plan will include enhanced hiring efforts to support planned global clinical trial execution in DMD, as well as fo…

of this Form 8-K shall be deemed to be furnished and not filed: 99.1 Press Release issued by Entrada Therapeutics, Inc. on March 24 , 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entrada Therapeutics, Inc. Date: March 24, 2025 /s/ Dipal Doshi Dipal Doshi Chief E…

Other Events. On March 24, 2025, the Company announced the receipt of authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product for a Phase 1/2 multiple ascending dose (“MAD”) clinical study of ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (“DMD”) in patients with a confirmed mutation in the DMD gene amenable to exon 45 skipping. ENTR-601-45 i…

Results of Operations and Financial Condition. On February 27, 2025, Entrada Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2024 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes…

Other Events. On February 24, 2025, the Company announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and provided authorization for a Phase 1b multiple ascending dose clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (“DMD”) in non-ambulatory and ambulatory adult patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. ENTR-601-44 is Entrada’s lead product candidate within its D…

Other Events. On February 3, 2025, the Company announced the receipt of authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product for a Phase 1/2 multiple ascending dose clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (“DMD”) in patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. ENTR-601-44 is Entr…

Results of Operations and Financial Condition. On January 15, 2025, Entrada Therapeutics, Inc. (the “Company”) presented at the 43 rd Annual J.P. Morgan Healthcare Conference, which presentation included certain preliminary financial results as of and for the fiscal year ended December 31, 2024. Specifically, the Company announced that its cash resources, which consist of cash, cash equivalents and marketable securities, were approximately $420.0 million as of December 31, 2024 and that it ex…

Results of Operations and Financial Condition On November 5, 2024, Entrada Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2024 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes o…

Results of Operations and Financial Condition On August 13, 2024, Entrada Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2024 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Sect…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On June 24, 2024, Entrada Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a limited number of purchasers relating to a registered direct offering (the “Offering”) of 3,367,003 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $14.85 per share and, in lieu of Common Stock to certain purc…

Other Events. Update on ENTR-601-44 On June 24, 2024, the Company announced positive preliminary data from its Phase 1 clinical trial of ENTR-601-44, its most advanced product candidate being developed for patients with DMD. The data announced is based upon data collected to date, is aggregated based upon the placebo and study drug groups and does not include urinary biomarkers for its 6 mg/kg cohort. The primary objective of the Company’s Phase 1 clinical trial was to evaluate the safety and…

Results of Operations and Financial Condition On May 7, 2024, Entrada Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section…

Results of Operations and Financial Condition On March 13, 2024, Entrada Therapeutics, Inc. announced its financial results for the year ended December 31, 2023 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Sect…